Cargando…

Contemporary management of anaemia, erythropoietin resistance and cardiovascular risk in patients with advanced chronic kidney disease: a nationwide analysis

BACKGROUND: Optimal management of chronic kidney disease (CKD) anaemia remains controversial and few studies have evaluated real-world management of anaemia in advanced CKD in the context of guideline recommendations. METHODS: We performed an observational study from the Swedish Renal Registry evalu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Evans, Marie, Bower, Hannah, Cockburn, Elinor, Jacobson, Stefan H, Barany, Peter, Carrero, Juan-Jesus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577763/ https://www.ncbi.nlm.nih.gov/pubmed/33123358 http://dx.doi.org/10.1093/ckj/sfaa054

Ejemplares similares

Factors affecting pre-end-stage kidney disease haemoglobin control and outcomes following dialysis initiation: a nationwide study
por: Xu, Yang, et al.
Publicado: (2021)

Initiation of sodium polystyrene sulphonate and the risk of gastrointestinal adverse events in advanced chronic kidney disease: a nationwide study
por: Laureati, Paola, et al.
Publicado: (2019)

Secondary hyperparathyroidism and adverse health outcomes in adults with chronic kidney disease
por: Xu, Yang, et al.
Publicado: (2021)

Erythropoietin, uncertainty principle and cancer related anaemia
por: Clark, Otavio, et al.
Publicado: (2002)

Cinacalcet use and the risk of cardiovascular events, fractures and mortality in chronic kidney disease patients with secondary hyperparathyroidism
por: Evans, Marie, et al.
Publicado: (2018)

Timing of dialysis initiation to reduce mortality and cardiovascular events in advanced chronic kidney disease: nationwide cohort study
por: Fu, Edouard L, et al.
Publicado: (2021)

Management of anaemia in CKD—the relative importance of erythropoietin and iron
por: Agarwal, Rajiv
Publicado: (2011)

Precision Medicine in Erythropoietin Deficiency and Treatment Resistance: A Novel Approach to Management of Anaemia in Chronic Kidney Disease
por: Yugavathy, Nava, et al.
Publicado: (2023)

Cisplatin-associated anaemia treated with subcutaneous erythropoietin. A pilot study.
por: Cascinu, S., et al.
Publicado: (1993)

Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia.
por: Barosi, G., et al.
Publicado: (1998)

Plasma potassium ranges associated with mortality across stages of chronic kidney disease: the Stockholm CREAtinine Measurements (SCREAM) project
por: Gasparini, Alessandro, et al.
Publicado: (2019)

Meta-Analysis of Randomized Controlled Trials on Androgens versus Erythropoietin for Anaemia of Chronic Kidney Disease: Implications for Developing Countries
por: Adamu, B., et al.
Publicado: (2012)

Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia.
por: Thews, O., et al.
Publicado: (1998)

Anaemia at discharge from the intensive care unit is associated with an inappropriate erythropoietin response
por: Bateman, A, et al.
Publicado: (2005)

Albuminuria as a Predictor of Cardiovascular Outcomes in Patients With Acute Myocardial Infarction
por: Mok, Yejin, et al.
Publicado: (2019)

Efficacy & safety of continuous erythropoietin receptor activator (CERA) in treating renal anaemia in diabetic patients with chronic kidney disease not on dialysis
por: Vankar, Sameer G., et al.
Publicado: (2014)

Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: a randomized controlled trial
por: Johnson, David Wayne, et al.
Publicado: (2008)

The effect of recombinant human erythropoietin treatment on tumour radiosensitivity and cancer-associated anaemia in the mouse.
por: Joiner, B., et al.
Publicado: (1993)

Response of patients with sickle cell anaemia and end-stage renal disease to erythropoietin treatment
por: Zumrutdal, Aysegul
Publicado: (2010)

Blood pressure and kidney outcomes in patients with severely decreased glomerular filtration rate: a nationwide observational cohort study
por: Al-Sodany, Ehab, et al.
Publicado: (2022)

Contemporary Cardiovascular Imaging Advancements and Social Media
por: Covas, Pedro, et al.
Publicado: (2021)

Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib: an active agent only in non progressive patients
por: Duffaud, Florence, et al.
Publicado: (2012)

Oxidative Stress and Cardiovascular Complications in Chronic Kidney Disease, the Impact of Anaemia
por: Nuhu, Faisal, et al.
Publicado: (2018)

Surgical versus endovascular intervention for vascular access thrombosis: a nationwide observational cohort study
por: Lundström, Ulrika Hahn, et al.
Publicado: (2022)

Erythropoietin (EPO) in acute kidney injury
por: Moore, Elizabeth, et al.
Publicado: (2011)

Novel glucose-lowering drugs and the risk of acute kidney injury in routine care; the Stockholm CREAtinine Measurements (SCREAM) project
por: Alkas, Jim, et al.
Publicado: (2022)

Age-related pattern and monocyte-acquired haemozoin associated production of erythropoietin in children with severe malarial anaemia in Ghana
por: Abugri, James, et al.
Publicado: (2014)

Once-monthly continuous erythropoietin receptor activator (CERA) for haemoglobin maintenance in haemodialysis patients with chronic renal anaemia
por: Duman, Neval, et al.
Publicado: (2014)

Treatment of Anemia in Kidney Disease: Beyond Erythropoietin
por: Wish, Jay B.
Publicado: (2021)

Fractures and their sequelae in non-dialysis-dependent chronic kidney disease: the Stockholm CREAtinine Measurement project
por: Runesson, Björn, et al.
Publicado: (2019)

Combination with intravenous iron supplementation or doubling erythropoietin dose for patients with chemotherapy-induced anaemia inadequately responsive to initial erythropoietin treatment alone: study protocol for a randomised controlled trial
por: Chen, Lin, et al.
Publicado: (2016)

Advances in Understanding the Effects of Erythropoietin on Renal Fibrosis
por: Zhang, Yangyang, et al.
Publicado: (2020)

Erythropoietin prevents dementia in hemodialysis patients: a nationwide population-based study
por: Hung, Peir-Haur, et al.
Publicado: (2019)

Immunosuppression Adherence in Stable Kidney Transplant Patients Converted From Immediate- to Prolonged-Release Tacrolimus in Clinical Practice: A Norwegian Study
por: Abedini, Sadollah, et al.
Publicado: (2018)

Does erythropoietin slow progression of chronic kidney disease?
por: Nasri, Hamid, et al.
Publicado: (2013)

Effects of Angiotensin II on Erythropoietin Production in the Kidney and Liver
por: Yasuoka, Yukiko, et al.
Publicado: (2021)

Burden of Anemia in Chronic Kidney Disease: Beyond Erythropoietin
por: Hanna, Ramy M., et al.
Publicado: (2020)

Time in Therapeutic Range and Outcomes After Warfarin Initiation in Newly Diagnosed Atrial Fibrillation Patients With Renal Dysfunction
por: Szummer, Karolina, et al.
Publicado: (2017)

Kidney Function, Kidney Function Decline, and the Risk of Dementia in Older Adults: A Registry-Based Study
por: Xu, Hong, et al.
Publicado: (2021)

Anti-erythropoietin antibody levels and its association with anaemia in different strains of semi-immune mice infected with Plasmodium berghei ANKA
por: Helegbe, Gideon Kofi, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_uqd2pl8nef2hon3rbrhb8b842b